NewsAI-assisted

Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader

Evotec and BMS secure a second FDA IND acceptance for a CELMoD degrader, with Phase 1 entry targeted for 2027.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 19, 20262 min read
Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
90/ 100
Trust score
High confidence

A second FDA IND acceptance under the Evotec–Bristol Myers Squibb protein degradation partnership signals that CELMoD agent pipelines are maturing fast enough to demand early CMC and GMP readiness planning from manufacturing and regulatory teams well ahead of Phase 1 entry.

The accepted candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a Phase 1 clinical trial in 2027. It follows the first partnered candidate, which entered a Phase 1 study in advanced clear cell renal cell carcinoma in March 2026. The collaboration, originally established with Celgene in 2018 and expanded in 2022 following the Bristol Myers Squibb acquisition, pairs Evotec's PanOmics and PanHunter platforms with BMS's proprietary CELMoD agent library to advance molecular glue degraders across oncology and adjacent indications.

For QA directors and regulatory affairs leads, the mechanistic profile of CELMoD agents introduces complexity that conventional small-molecule CMC frameworks do not fully address. Unlike standard inhibitors, molecular glue degraders induce neomorphic interactions between the E3 ubiquitin ligase CRBN and substrate proteins, driving ubiquitination and targeted protein degradation. That mechanism of action places distinct demands on analytical characterisation, stability profiling, and process validation, areas where IND-stage documentation must anticipate 21 CFR Part 211 expectations while aligning with ICH Q10 quality system principles across the development lifecycle.

The platform's throughput is relevant context for plant heads assessing future manufacturing scope. Evotec applies high-end proteomics and transcriptomics at industrial scale, with PanHunter integrating multi-omics datasets to prioritise candidates for lead optimisation. Two IND acceptances in under eight years from a single collaboration suggests the discovery engine is generating candidates at a pace that will compress the timeline between preclinical nomination and GMP clinical supply requirements.

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, described the second acceptance as evidence of “repeatability and productivity” in the discovery platform, noting the team is “systematically translating complex biology into development candidates.”

The 2027 Phase 1 entry target for the second CELMoD candidate sets a near-term checkpoint for CMC teams to confirm that analytical methods, reference standards, and sterility assurance protocols are aligned with the regulatory package submitted at IND.

Source: Evotec SE via evotec.com, November 19, 2026.
Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →